MNMD

Mind Medicine MindMed (MNMD)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNMD
DataOraFonteTitoloSimboloCompagnia
09/05/202422:01Business WireMindMed to Participate at May Investor ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
09/05/202414:00Business WireNew Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the USNASDAQ:MNMDMind Medicine MindMed Inc
08/05/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNMDMind Medicine MindMed Inc
08/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNMDMind Medicine MindMed Inc
08/05/202422:01Business WireMindMed Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:MNMDMind Medicine MindMed Inc
04/05/202414:00Business WireMindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New YorkNASDAQ:MNMDMind Medicine MindMed Inc
02/05/202413:00Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
25/04/202413:00Business WireMindMed to Present at Upcoming May Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
02/04/202413:00Business WireMindMed to Present at Upcoming April Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
01/04/202423:00Business WireMindMed Announces Voluntary Delisting from Cboe CanadaNASDAQ:MNMDMind Medicine MindMed Inc
11/03/202412:00Business WireMindMed to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413:13Business WireMind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private PlacementNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413:09Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:MNMDMind Medicine MindMed Inc
07/03/202412:00Business WireMindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202419:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202415:00Business WireMindMed to Host Conference Call and Webcast to Discuss Data Update for MM120NASDAQ:MNMDMind Medicine MindMed Inc
29/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413:05Business WireMindMed Reports 2023 Financial Results and Business UpdatesNASDAQ:MNMDMind Medicine MindMed Inc
22/02/202413:00Business WireMindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
07/02/202413:00Business WireMindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
08/01/202413:45Business WireMindMed Announces Business Update and Anticipated Milestones for 2024NASDAQ:MNMDMind Medicine MindMed Inc
14/12/202313:30Business WireMindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
02/11/202321:01Business WireMindMed Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:MNMDMind Medicine MindMed Inc
26/10/202313:30Business WireMindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
24/10/202313:30Business WireMindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)NASDAQ:MNMDMind Medicine MindMed Inc
03/10/202313:30Business WireMindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressNASDAQ:MNMDMind Medicine MindMed Inc
15/09/202323:27Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MNMDMind Medicine MindMed Inc
14/09/202313:30Business WireMindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitNASDAQ:MNMDMind Medicine MindMed Inc
12/09/202313:30Business WireMindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)NASDAQ:MNMDMind Medicine MindMed Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNMD
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network